Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Curi RMB Capital LLC

Curi RMB Capital LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 18.1% during the 3rd quarter, Holdings Channel reports. The firm owned 84,873 shares of the medical instruments supplier’s stock after purchasing an additional 13,030 shares during the quarter. Curi RMB Capital LLC’s holdings in Becton, Dickinson and Company were worth $20,463,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Empowered Funds LLC lifted its holdings in Becton, Dickinson and Company by 40.2% in the 1st quarter. Empowered Funds LLC now owns 4,439 shares of the medical instruments supplier’s stock valued at $1,098,000 after purchasing an additional 1,273 shares in the last quarter. Avantax Advisory Services Inc. lifted its stake in shares of Becton, Dickinson and Company by 5.0% in the first quarter. Avantax Advisory Services Inc. now owns 6,354 shares of the medical instruments supplier’s stock worth $1,572,000 after buying an additional 301 shares in the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in Becton, Dickinson and Company during the first quarter worth about $148,000. Kingsview Wealth Management LLC grew its stake in Becton, Dickinson and Company by 7.4% during the 1st quarter. Kingsview Wealth Management LLC now owns 4,306 shares of the medical instruments supplier’s stock valued at $1,065,000 after acquiring an additional 296 shares in the last quarter. Finally, HBK Sorce Advisory LLC raised its holdings in Becton, Dickinson and Company by 5.7% in the 1st quarter. HBK Sorce Advisory LLC now owns 3,167 shares of the medical instruments supplier’s stock valued at $784,000 after acquiring an additional 172 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.0 %

Shares of BDX opened at $231.26 on Thursday. The company’s 50-day simple moving average is $236.56 and its 200-day simple moving average is $235.10. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89. The stock has a market capitalization of $66.84 billion, a PE ratio of 38.93, a P/E/G ratio of 1.72 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the company posted $3.42 earnings per share. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. Analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.80%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BDX shares. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.